Carl B. Camras: Difference between revisions
No edit summary |
|||
| Line 21: | Line 21: | ||
}} |
}} |
||
'''Carl B. Camras''' (1953-2009) is a world renowned glaucoma specialist and research scientist. He discovered a new class of drugs to treat [[glaucoma]] |
'''Carl B. Camras''' (1953-2009) is a world renowned glaucoma specialist and research scientist. He discovered a new class of drugs to treat [[glaucoma]]--prostaglandin analogues. Specifically, he developed [[latanoprost]] sold under the trade name [[Xalatan]], which is most widely used glaucoma medication. <ref>http://app1.unmc.edu/publicaffairs/todaysite/sitefiles/today_full.cfm?match=5604</ref> |
||
==Biography== |
==Biography== |
||
Revision as of 18:10, 17 June 2010
Carl B. Camras, MD | |
|---|---|
| File:Carl Camras MD.jpg Carl Camras | |
| Born | November 23, 1953 Glencoe, Illinois |
| Died | April 14, 2009 |
| Education | Yale University, Columbia University, UCLA |
| Known for | Development of the prostaglandin analogues for the treatment of glaucoma |
| Medical career | |
| Profession | Ophthalmologist, Chairman UNMC Department of Ophthalmology and Visual Sciences |
| Institutions | University of Nebraska Medical Center |
| Research | Glaucoma |
Carl B. Camras (1953-2009) is a world renowned glaucoma specialist and research scientist. He discovered a new class of drugs to treat glaucoma--prostaglandin analogues. Specifically, he developed latanoprost sold under the trade name Xalatan, which is most widely used glaucoma medication. [1]
Biography
Carl Camras grew up in Chicago, Illinois. He was the son of the engineer and inventor Marvin Camras who held over 550 patents. His father invented magnetic recording which was later used on VCR tapes and computer disks.[2]
Undergraduate Work
As a molecular biophysics and biochemistry major at Yale University, Dr. Camras first conceived the idea that low doses of prostaglandins could be effective in lowering intraocular pressure in glaucoma.
Medical School
In medical school at Columbia University, Dr. Camras sought out a research adviser who would work with him on his project. After many rejections, he partnered with a renowned researcher-novelist Dr. László Z. Bitó who agreed to work with him on the project.[3]